07Oct 2022
Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st‐line BRAF‐targeted therapy

Retrospective review of outcomes associated with metastatic melanoma patients treated with 1st‐line BRAF‐targeted therapy

This study conducted a retrospective review of clinical outcomes in 25 patients treated over the last 3 years with 1st‐line BRAF‐targeted therapy in a real‐world clinical setting at a UK‐based tertiary centre. The overall response rate was similar, at 64%. However, only five patients went on to receive 2nd‐line immunotherapy. In a modern‐day, real‐world setting, these patients should be counselled that only 1 in 5 are likely to receive 2nd‐line immunotherapy, and their survival times are expected to be short.

  • #dermatology

Like

Save

Share